Jazz Pharmaceuticals (JAZZ) announced Monday morning that its Phase 3 study of JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints compared to placebo.
from RTT - Before the Bell http://ift.tt/2mLk74i
via IFTTT
No comments:
Post a Comment